Additionally, the combination of temsirolimus, an allosteric mammalian target of rapamycin inhibitor, and doxorubicin, a chemotherapeutic agent, has been reported to enhance the anti-tumour effect in HCC cells [67]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.